Thursday, June 6, 2013

Otsuka and UCB have received approval for E Keppra (levetiracetam) as adjunctive therapy for treatment of Epilepsy in pediatric patients aged four years and older

Otsuka Pharmaceutical Co., Ltd. and UCB Japan Co., Ltd have obtained regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra® 250 mg and 500 mg Tablets (levetiracetam) as adjunctive therapy in combination with other antiepileptic drugs in the treatment of “partial-onset seizures in pediatric patients with epilepsy aged four years and older.

E Keppra® is an antiepileptic drug which does not share the mechanism of action with any conventional antiepileptic drugs, and therefore the additional indication offers a new treatment option for pediatric patients and contributes to pharmacotherapy for epilepsy in these patients




Enter your email address:






Delivered by FeedBurner